

- [Dossier preparation manuals](#)
- [Q&A](#)
- [Create support request](#)
- [IUCLID user community](#)
- [Additional information](#)
- [Video tutorials](#)

SuperUser EPA/ORD/CCTE/SCDCD

- User Settings
- Logout
  
- Dashboard
- Substances
- Sodium 3-(allyloxy)-2-hydroxypropan...

**Filtered aggr\_1**

**427ab603-f1bf-4501-a1e0-735b879ae19a**

View Dossiers

Validate

- Export to i6z
- Extract to dataset
- Create component PDF/RTF
- Create document PDF/RTF
- Compare
- Generate report
- Dissemination preview

Type at least 3 characters

REACH Complete

Sodium 3-(allyloxy)-2-hydroxypropanesulphonate

- 1 General information  
7
- 2 Classification & Labelling and PBT assessment
- 3 Manufacture, use and exposure
- 4 Physical and chemical properties  
17
- 5 Environmental fate and pathways  
9
- 6 Ecotoxicological information  
11
- 7 Toxicological information  
24
  - 70e2ca2b-b386-4347-8937-864511113138
  - 7.1 Toxicokinetics, metabolism and distribution  
1

- 7.2 Acute Toxicity  
3
- 7.3 Irritation / corrosion  
5
- 7.4 Sensitisation  
2
- 7.5 Repeated dose toxicity  
5
  - 7.5.1 Repeated dose toxicity: oral  
3
    - cbdabc63-c115-4951-a5bc-812b4a5f6378
    - bda43789-9094-4781-81e6-ea2545923b7e
    - 4e0a30ec-2b41-4f59-a948-f7539e9bb2e9
  - 7.5.2 Repeated dose toxicity: inhalation  
1
  - 7.5.3 Repeated dose toxicity: dermal  
1
  - 7.5.4 Repeated dose toxicity: other routes
- 7.6 Genetic toxicity  
3
- 7.7 Carcinogenicity
- 7.8 Toxicity to reproduction  
4
- 7.9 Specific investigations
- 7.10 Exposure related observations in humans
- 7.11 Toxic effects on livestock and pets
- 7.12 Additional toxicological information

- 8 Analytical methods
- 9 Residues in food and feedingstuffs
- 10 Effectiveness against target organisms
- 11 Guidance on safe use
- 12 Literature search
- 13 Assessment reports
- 14 Information requirements
- Inherited templates

UUID cbdabc63-c115-4951-a5bc-812b4a5f6378 ☐ Hide empty fields

- Compare Document

0

1

0



Administrative data

Data source

Materials and methods

Results and discussion

Overall remarks, attachments

Applicant's summary and conclusion

Administrative data

Endpoint  
short-term repeated dose toxicity: oral

Type of information  
experimental study

Adequacy of study  
key study

☐ Robust study summary

☐ Used for classification

☐ Used for SDS

Study period

Reliability  
1 (reliable without restriction)

Rationale for reliability incl. deficiencies

Data waiving

Justification for data waiving

Justification for type of information

Attached justification

# Attached justification Reason / purpose Actions

Cross-reference

# Reason / purpose for cross-reference Related information Remarks Actions

Data source

Reference

- study report | Unnamed | 2008 | 2008-02-28

Data access

Data protection claimed

Materials and methods

Test guideline

# Qualifier Guideline Version / remarks Deviations Actions 1

Qualifier  
according to guideline  
Guideline  
other:

Version / remarks

Deviations

2

Qualifier  
equivalent or similar to guideline  
Guideline

OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)

Version / remarks

Deviations

Principles of method if other than guideline

GLP compliance

yes

Limit test

no

Test material

Test material information

- Unnamed | Unnamed | sodium 2-hydroxy-3-(prop-2-en-1-yloxy)propane-1-sulfonate | EC 258-004-5 | 52556-42-0 | Unnamed | sodium hydroxide | EC 215-185-5 | 1310-73-2 | Unnamed | 3-(allyloxy)propane-1,2-diol | EC 204-620-4 | 123-34-2 | Unnamed | disodium 2-hydroxy-3-(3-sulfonatopropoxy)propane-1-sulfonate

Additional test material information

Specific details on test material used for the study

Specific details on test material used for the study (confidential)

Test animals

Species

rat

Strain

Crlj: CD(SD)

Details on species / strain selection

Sex

male/female

Details on test animals or test system and environmental conditions

Administration / exposure

Route of administration

oral: gavage

Details on route of administration

Vehicle

Details on oral exposure

Analytical verification of doses or concentrations

Details on analytical verification of doses or concentrations

Duration of treatment / exposure

28 days

Frequency of treatment

Doses / concentrations

# Dose / conc. Remarks Actions

No. of animals per sex per dose

Control animals

Details on study design

Positive control

#### Examinations

Observations and examinations performed and frequency

Sacrifice and pathology

Optional endpoint(s)

Other examinations

Statistics

Any other information on materials and methods incl. tables

#### Results and discussion

##### Results of examinations

Clinical signs

Description (incidence and severity)

Mortality

Description (incidence)

Body weight and weight changes

Description (incidence and severity)

Food consumption and compound intake (if feeding study)

Description (incidence and severity)

Food efficiency

Description (incidence and severity)

Water consumption and compound intake (if drinking water study)

Description (incidence and severity)

Ophthalmological findings

Description (incidence and severity)

Haematological findings

Description (incidence and severity)

Clinical biochemistry findings

Description (incidence and severity)

---

Endocrine findings

---

Description (incidence and severity)

---

Urinalysis findings

---

Description (incidence and severity)

---

Behaviour (functional findings)

---

Description (incidence and severity)

---

Immunological findings

---

Description (incidence and severity)

---

Organ weight findings including organ / body weight ratios

---

Description (incidence and severity)

---

Gross pathological findings

---

Description (incidence and severity)

---

Neuropathological findings

---

Description (incidence and severity)

---

Histopathological findings: non-neoplastic

---

Description (incidence and severity)

---

Histopathological findings: neoplastic

---

Description (incidence and severity)

---

Other effects

---

Description (incidence and severity)

---

Details on results

---

**Effect levels**

---

# Key result Dose descriptor Effect level Based on Sex Basis for effect level Remarks on result Actions 1

☐ Key result

Dose descriptor

NOAEL

Effect level

150 mg/kg bw/day (actual dose received)

Based on

test mat.

Sex

male/female

Basis for effect level

- other:

Remarks on result

---

**Target system / organ toxicity**

---

# Key result Critical effects observed Lowest effective dose / conc. System Organ Treatment related Dose response relationship Relevant for humans Actions 1

☐ Key result  
Critical effects observed  
not specified  
Lowest effective dose / conc.  
System  
Organ

Treatment related  
Dose response relationship  
Relevant for humans

---

Any other information on results incl. tables

---

Overall remarks, attachments

---

Overall remarks

---

Attachments

# Type Attached (confidential) document Attached (sanitised) documents for publication Remarks Actions

---

Illustration (picture/graph)

Applicant's summary and conclusion

---

Conclusions

---

Executive summary

TOP

- [Dashboard](#)
- [Substances](#)
- [Mixtures / Products](#)
- [Articles](#)
- [Categories](#)

Toolbox

- [Template](#)
- [Manage Reports](#)

Inventory manager

- [Contact](#)
- [Legal entity](#)
- [Sites](#)
- [Reference substance](#)
- [Test material](#)
- [Literature reference](#)

User management

- [User Settings](#)
- [Users](#)
- [Roles](#)

## About IUCLID

- [About](#)
- [Help](#)